Shopping Cart 0
Cart Subtotal
USD 0

Covance Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Covance Inc (Covance), a subsidiary of LabCorp, is a drug development company that offers contract research and manufacturing services. The company offers a broad range of early-stage and late-stage product development services to pharmaceutical, biotechnology and medical device companies. It also offers services including laboratory testing for agrochemical, chemical and food industries. The early-stage development services that the company offers include preclinical and clinical pharmacology services and discovery support services. Its late-stage development services include Phase II-IV clinical development, central laboratory and market access services. The company operates across the US, Europe, South America and Asia-Pacific. Covance is headquartered in Princeton, New Jersey, the US.

Covance Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Covance Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Covance Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Covance Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Covance Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Covance Inc, Medical Devices Deals, 2012 to YTD 2018 10

Covance Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Covance Inc, Pharmaceuticals & Healthcare, Deal Details 13

Private Equity 13

Chicago Growth Partners Acquires Caprion Proteomics For USD 29 Million 13

Partnerships 14

Emulate Enters into Agreement with Covance 14

Corcept Therapeutics Enters into Agreement with Chiltern for CORT125134 15

Motif Bio Enters into Agreement with Covance 16

Covance Enters into Co-Development Agreement with Sihuan Pharma 17

Covance Enters into Co-Development Agreement with Novartis Institutes for BioMedical Research 18

Covance Enters into Research Agreement with Frenova Renal Research 19

Covance And Pathoquest Enter Into Agreement For Sequencing-Based Biosafety Assessments 20

Covance And Royal Liverpool and Broadgreen University Hospitals Enter Into Agreement To Offer Clinical Trials 21

GNS Healthcare Enters Into Co-Development Agreement With Covance 22

Bayer HealthCare Enters Into Agreement With Covance 23

Covance Enters Into Co-Development Agreement With Inserm Transfert And Inserm Transfert Initiative 24

Debt Offering 26

Covance Completes Private Placement Of Notes Due 2025 For USD 95 Million 26

Covance Completes Private Placement Of Notes Due 2023 For USD 90 Million 27

Covance Completes Private Placement Of Notes Due 2018 For USD 15 Million 28

Covance Completes Private Placement Of Notes Due 2020 For USD 50 Million 29

Asset Transactions 30

LabCorp Acquires High-Complexity Genomic Lab From Covance 30

Acquisition 31

Eurofins Acquires Covance from LabCorp 31

LabCorp Acquires Chiltern International for USD1.2 Billion 33

Chiltern International Acquires Integrated Development Associates 35

LabCorp Acquires Covance for USD6.1 Billion 36

Chiltern International Acquires Pacific Clinical Research 38

BioLegend Acquires Covance Antibody Services from Covance 39

Chiltern Acquires Ockham, Contract Research Organization 40

Covance Acquires Medaxial 41

Kester Capital Sells Its Stake In Chiltern For USD 220 Million 42

Covance Inc-Key Competitors 43

Covance Inc-Key Employees 44

Covance Inc-Locations And Subsidiaries 45

Head Office 45

Other Locations & Subsidiaries 45

Recent Developments 50

Other Significant Developments 50

Jan 08, 2018: Covance Introduces Dedicated Offering Designed for Biotech, Medical Device and Diagnostics Companies 50

Appendix 51

Methodology 51

About GlobalData 51

Contact Us 51

Disclaimer 51


List Of Figure

List of Figures

Covance Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Covance Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Covance Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Covance Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Covance Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Covance Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Covance Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Covance Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Covance Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Covance Inc, Pharmaceuticals & Healthcare, Key Facts 2

Covance Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Covance Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Covance Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Covance Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Covance Inc, Medical Devices Deals, 2012 to YTD 2018 10

Covance Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Chicago Growth Partners Acquires Caprion Proteomics For USD 29 Million 13

Emulate Enters into Agreement with Covance 14

Corcept Therapeutics Enters into Agreement with Chiltern for CORT125134 15

Motif Bio Enters into Agreement with Covance 16

Covance Enters into Co-Development Agreement with Sihuan Pharma 17

Covance Enters into Co-Development Agreement with Novartis Institutes for BioMedical Research 18

Covance Enters into Research Agreement with Frenova Renal Research 19

Covance And Pathoquest Enter Into Agreement For Sequencing-Based Biosafety Assessments 20

Covance And Royal Liverpool and Broadgreen University Hospitals Enter Into Agreement To Offer Clinical Trials 21

GNS Healthcare Enters Into Co-Development Agreement With Covance 22

Bayer HealthCare Enters Into Agreement With Covance 23

Covance Enters Into Co-Development Agreement With Inserm Transfert And Inserm Transfert Initiative 24

Covance Completes Private Placement Of Notes Due 2025 For USD 95 Million 26

Covance Completes Private Placement Of Notes Due 2023 For USD 90 Million 27

Covance Completes Private Placement Of Notes Due 2018 For USD 15 Million 28

Covance Completes Private Placement Of Notes Due 2020 For USD 50 Million 29

LabCorp Acquires High-Complexity Genomic Lab From Covance 30

Eurofins Acquires Covance from LabCorp 31

LabCorp Acquires Chiltern International for USD1.2 Billion 33

Chiltern International Acquires Integrated Development Associates 35

LabCorp Acquires Covance for USD6.1 Billion 36

Chiltern International Acquires Pacific Clinical Research 38

BioLegend Acquires Covance Antibody Services from Covance 39

Chiltern Acquires Ockham, Contract Research Organization 40

Covance Acquires Medaxial 41

Kester Capital Sells Its Stake In Chiltern For USD 220 Million 42

Covance Inc, Key Competitors 43

Covance Inc, Key Employees 44

Covance Inc, Other Locations 45

Covance Inc, Subsidiaries 48

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Covance Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Covance Inc (Covance), a subsidiary of LabCorp, is a drug development company that offers contract research and manufacturing services. The company offers a broad range of early-stage and late-stage product development services to pharmaceutical, biotechnology and medical device companies. It also offers services including laboratory testing for agrochemical, chemical and food industries. The early-stage development services that the company offers include preclinical and clinical pharmacology services and discovery support services. Its late-stage development services include Phase II-IV clinical development, central laboratory and market access services. The company operates across the US, Europe, South America and Asia-Pacific. Covance is headquartered in Princeton, New Jersey, the US.

Covance Inc-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Covance Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Covance Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Covance Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Covance Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Covance Inc, Medical Devices Deals, 2012 to YTD 2018 10

Covance Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Covance Inc, Pharmaceuticals & Healthcare, Deal Details 13

Private Equity 13

Chicago Growth Partners Acquires Caprion Proteomics For USD 29 Million 13

Partnerships 14

Emulate Enters into Agreement with Covance 14

Corcept Therapeutics Enters into Agreement with Chiltern for CORT125134 15

Motif Bio Enters into Agreement with Covance 16

Covance Enters into Co-Development Agreement with Sihuan Pharma 17

Covance Enters into Co-Development Agreement with Novartis Institutes for BioMedical Research 18

Covance Enters into Research Agreement with Frenova Renal Research 19

Covance And Pathoquest Enter Into Agreement For Sequencing-Based Biosafety Assessments 20

Covance And Royal Liverpool and Broadgreen University Hospitals Enter Into Agreement To Offer Clinical Trials 21

GNS Healthcare Enters Into Co-Development Agreement With Covance 22

Bayer HealthCare Enters Into Agreement With Covance 23

Covance Enters Into Co-Development Agreement With Inserm Transfert And Inserm Transfert Initiative 24

Debt Offering 26

Covance Completes Private Placement Of Notes Due 2025 For USD 95 Million 26

Covance Completes Private Placement Of Notes Due 2023 For USD 90 Million 27

Covance Completes Private Placement Of Notes Due 2018 For USD 15 Million 28

Covance Completes Private Placement Of Notes Due 2020 For USD 50 Million 29

Asset Transactions 30

LabCorp Acquires High-Complexity Genomic Lab From Covance 30

Acquisition 31

Eurofins Acquires Covance from LabCorp 31

LabCorp Acquires Chiltern International for USD1.2 Billion 33

Chiltern International Acquires Integrated Development Associates 35

LabCorp Acquires Covance for USD6.1 Billion 36

Chiltern International Acquires Pacific Clinical Research 38

BioLegend Acquires Covance Antibody Services from Covance 39

Chiltern Acquires Ockham, Contract Research Organization 40

Covance Acquires Medaxial 41

Kester Capital Sells Its Stake In Chiltern For USD 220 Million 42

Covance Inc-Key Competitors 43

Covance Inc-Key Employees 44

Covance Inc-Locations And Subsidiaries 45

Head Office 45

Other Locations & Subsidiaries 45

Recent Developments 50

Other Significant Developments 50

Jan 08, 2018: Covance Introduces Dedicated Offering Designed for Biotech, Medical Device and Diagnostics Companies 50

Appendix 51

Methodology 51

About GlobalData 51

Contact Us 51

Disclaimer 51


List Of Figure

List of Figures

Covance Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Covance Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Covance Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Covance Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Covance Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Covance Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Covance Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Covance Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Covance Inc, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Covance Inc, Pharmaceuticals & Healthcare, Key Facts 2

Covance Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Covance Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Covance Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Covance Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Covance Inc, Medical Devices Deals, 2012 to YTD 2018 10

Covance Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Chicago Growth Partners Acquires Caprion Proteomics For USD 29 Million 13

Emulate Enters into Agreement with Covance 14

Corcept Therapeutics Enters into Agreement with Chiltern for CORT125134 15

Motif Bio Enters into Agreement with Covance 16

Covance Enters into Co-Development Agreement with Sihuan Pharma 17

Covance Enters into Co-Development Agreement with Novartis Institutes for BioMedical Research 18

Covance Enters into Research Agreement with Frenova Renal Research 19

Covance And Pathoquest Enter Into Agreement For Sequencing-Based Biosafety Assessments 20

Covance And Royal Liverpool and Broadgreen University Hospitals Enter Into Agreement To Offer Clinical Trials 21

GNS Healthcare Enters Into Co-Development Agreement With Covance 22

Bayer HealthCare Enters Into Agreement With Covance 23

Covance Enters Into Co-Development Agreement With Inserm Transfert And Inserm Transfert Initiative 24

Covance Completes Private Placement Of Notes Due 2025 For USD 95 Million 26

Covance Completes Private Placement Of Notes Due 2023 For USD 90 Million 27

Covance Completes Private Placement Of Notes Due 2018 For USD 15 Million 28

Covance Completes Private Placement Of Notes Due 2020 For USD 50 Million 29

LabCorp Acquires High-Complexity Genomic Lab From Covance 30

Eurofins Acquires Covance from LabCorp 31

LabCorp Acquires Chiltern International for USD1.2 Billion 33

Chiltern International Acquires Integrated Development Associates 35

LabCorp Acquires Covance for USD6.1 Billion 36

Chiltern International Acquires Pacific Clinical Research 38

BioLegend Acquires Covance Antibody Services from Covance 39

Chiltern Acquires Ockham, Contract Research Organization 40

Covance Acquires Medaxial 41

Kester Capital Sells Its Stake In Chiltern For USD 220 Million 42

Covance Inc, Key Competitors 43

Covance Inc, Key Employees 44

Covance Inc, Other Locations 45

Covance Inc, Subsidiaries 48

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Covance Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.